Controlled release arginine α-ketoglutarate
An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.
1. A controlled release oral dosage formulation comprising:
arginine alpha-ketoglutarate in an amount of 60%; and
excipient materials comprising microcrystalline cellulose in an amount of 14%, cellulose acetate phthalate aqueous dispersion in an amount of 15%, polyvinylpyrrolidone in an amount of 3%, ethyl acetate in an amount of 2.5%, hydrous magnesium silicate in an amount of 1%, carboxy methyl ether in an amount of 4% and magnesium stearate in an amount of 0.5%;
wherein the formulation is characterized by releasing the arginine alpha- ketoglutarate in a manner so as to maintain a constant therapeutic level of arginine alpha-ketoglutarate in the blood over a period of four hours or more.
2. A controlled release oral dosage formulation comprising:
arginine alpha-ketoglutarate in an amount of 60%; and
excipient materials comprising microcrystalline cellulose in an amount of 10-30%, cellulose acetate phthalate aqueous dispersion in an amount of 5-25%, polyvinylpyrrolidone in an amount of 1-5%, ethyl acetate in an amount of 1-5%, hydrous magnesium silicate (talc) in an amount of 0.5-3%, carboxy methyl ether in an amount of 1-5% and magnesium stearate in an amount of 0.5-1.5%;
wherein the formulation is characterized by releasing the arginine alpha- ketoglutarate in a manner so as to maintain a constant therapeutic level of arginine alpha-ketoglutarate in the blood over a period of four hours or more.
3. The formulation of claim 1 or 2 , wherein the arginine α-ketoglutarate is present in an amount of from about 50 mg to about 1,000 mg.
4. The formulation of claim 1 or 2 , wherein the arginine α-ketoglutarate is present in an amount of from about 100mg to about 500 mg.
5. The formulation of claim 1 or 2 , wherein the arginine α-ketoglutarate is present in an amount of from about 300 mg.
6. The formulation of claim 1 or 2 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for a period of eight hours or more.
7. The formulation of claim 1 or 2 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for twelve hours or more.
8. The formulation of claim 1 or 2 , wherein the releasing is in a manner which maintains the therapeutic level of arginine α-ketoglutarate for 16 hours or more.